Search

Your search keyword '"D’Amato, D"' showing total 11 results
Start Over Author "D’Amato, D" Publisher elsevier ltd
11 results on '"D’Amato, D"'

2. Prognostic models and autoimmune liver diseases

Author

D'Amato, D, Carbone, M, D'Amato D., Carbone M., D'Amato, D, Carbone, M, D'Amato D., and Carbone M.

Abstract

Autoimmune liver diseases (AILDs) are complex diseases with unknown causes and immune-mediated pathophysiology. In primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) disease modifying drugs are available which improve patient quality and quantity of life. In primary sclerosing cholangitis (PSC) no medical therapy is available and the only accepted treatment is liver transplantation (LT). PBC, PSC and AIH possess features that describe the archetype of patients within each disorder. On the other hand, the classical disorders are not homogeneous, and patients within each diagnosis may present with a range of clinical, biochemical, serological, and histological findings. Singularly, they are considered rare diseases, but together, they account for approximately 20% of LTs in Europe and USA. Management of these patients is complex, as AILDs are relatively uncommon in clinical practice with challenges in developing expertise, disease presentation can be sneaky, clinical phenotypes and disease course are heterogeneous. Prognostic models are key tools for clinicians to assess patients’ risk and to provide personalized care to patients. Aim of this review is to discuss challenges of the management of AILDs and how the available prognostic models can help. We will discuss the prognostic models developed in AILDs, with a special focus on the prognostic models that can support the clinical management of patients with AILDs: in PBC models based on ursodeoxycholic acid (UDCA) response and markers of liver fibrosis; in PSC several markers including biochemistry, disease stage and radiological semiquantitative markers; and finally in AIH, markers of disease stage and disease activity.

Published
2023

7. Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid

Author

De Vincentis, A., D'Amato, D., Cristoferi, L., Gerussi, A., Malinverno, F., Lleo, A., Colapietro, F., Marra, F., Galli, A., Fiorini, C., Coco, B., Brunetto, M., Niro, G.A., Cotugno, R., Saitta, C., Cozzolongo, R., Losito, F., Giannini, E.G., Labanca, S., Marzioni, M., Marconi, G., Morgando, A., Pellicano, R., Vanni, E., Cazzagon, N., Floreani, A., Chessa, L., Morelli, O., Muratori, L., Pellicelli, A., Pompili, M., Ponziani, F., Rosina, F., Russello, M., Cannavò, M., Simone, L., Storato, S., Viganò, M., Abenavoli, L., D'Antò, M., De Gasperi, E., Distefano, M., Scifo, G., Zolfino, T., Calvaruso, V., Cuccorese, G., Pace Palitti, V., Sacco, R., Bertino, G., Frazzetto, E., Alvaro, D., Mulinacci, G., Palermo, A., Galati, G., Ronca, V., Zuin, M., Claar, E., Izzi, A., Picardi, A., Invernizzi, P., Vespasiani-Gentilucci, U., and Carbone, M.

Published
2022
Full Text
View/download PDF

11. Influence of particle size on the SARS-CoV-2 spike protein detection using IgG-capped gold nanoparticles and dynamic light scattering.

Author

Ligiero CBP, Fernandes TS, D'Amato DL, Gaspar FV, Duarte PS, Strauch MA, Fonseca JG, Meirelles LGR, Bento da Silva P, Azevedo RB, Aparecida de Souza Martins G, Archanjo BS, Buarque CD, Machado G, Percebom AM, and Ronconi CM

Abstract

Due to the unprecedented and ongoing nature of the coronavirus outbreak, the development of rapid immunoassays to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its highly contagious variants is an important and challenging task. Here, we report the development of polyclonal antibody-functionalized spherical gold nanoparticle biosensors as well as the influence of the nanoparticle sizes on the immunoassay response to detect the SARS-CoV-2 spike protein by dynamic light scattering. By monitoring the increment in the hydrodynamic diameter (ΔD H ) by dynamic light scattering measurements in the antigen-antibody interaction, SARS-CoV-2 S-protein can be detected in only 5 min. The larger the nanoparticles, the larger ΔD H in the presence of spike protein. From adsorption isotherm, the calculated binding constant ( K D ) was 83 nM and the estimated limit of detection was 13 ng/mL (30 pM). The biosensor was stable up to 90 days at 4 °C. Therefore, the biosensor developed in this work could be potentially applied as a fast and sensible immunoassay to detect SARS-CoV-2 infection in patient samples., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article., (© 2022 Elsevier Ltd. All rights reserved.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results